Publication at First Faculty of Medicine, Faculty of Medicine in Pilsen |
2017
Abstract
Osimertinib belongs to third generation of tyrosine kinase inhibitors (TKIs) that target the epidermoid growth factor receptor (EGFR). Good tolerance of osimertinib was demonstrated by the studies of phase I and II.
Recently published phase III study (AURA3) compared effectiveness of osimertinib against platinum doublet in patients with documented T790M mutation after previous treatment with 1st or 2nd generation EGFR-TKIs. The result was as significantly as clinically improvement in time to progression (PFS), objective response rate (ORR) and better safety profile and quality of life of patients.
Osimertinib therefore become the new standard for this group of patients with non small cell lung cancer (NSCLC).